Lumida
/ARGX
⌘K
argenx SE

argenx SE

ARGX
$860.55USD↑+0.30%+2.58 today

MARKET CAP

39.2B

P/E (TTM)

38.3x

FWD P/E

27.9x

DAY RANGE

$844 – $863

52W RANGE

$561
$954

AI Summary

Stalk
StalkMedium

The stock remains in a Stage 2 advance with its higher-high/higher-low sequence intact above the rising 50-day MA despite a corrective pullback. A Bearish Pivot Point pattern signals mean-reversion rather than distribution breakdown. Price is pulling back into the short EMAs and 50-day MA and requires clear support and acceptance through the EMAs before resuming upside. We defer execution until a confirming bounce and reclaim of the EMAs.

  • ↑Q1 2026 net product sales hit $1.3B (+63% YoY), driven by VivGuard uptake
  • ↑Strong cash position of $4.9B provides flexibility for R&D and trial funding
  • ↓Elevated leverage risk could constrain capacity in adverse economic conditions
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Argenx SE (NASDAQ: ARGX) is a leading clinical-stage biopharmaceutical company specializing in immunology, particularly for neuromuscular diseases like Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). With its flagship product, VivGuard, the company is positioned to address significant unmet medical needs through innovative therapies. The firm's strategic roadmap, Vision 2030, aims to expand its patient base and product offerings while converting its robust pipeline into valuable therapies in the growing autoimmune space.

Bull says

  • ↑Q1 2026 net product sales hit $1.3B (+63% YoY), driven by VivGuard uptake
  • ↑Strong cash position of $4.9B provides flexibility for R&D and trial funding
  • ↑Pipeline primed for ocular and seronegative MG label expansions with positive preclinical data
  • ↑Operating profit reached $394M (30% margin), reflecting improving operating leverage
  • ↑Over 15,000 patients treated globally, highlighting solid market penetration and physician adoption
  • ↑Positive analyst upgrades and robust earnings momentum support further valuation gains

Bear says

  • ↓Elevated leverage risk could constrain capacity in adverse economic conditions
  • ↓Negative earnings yield suggests overvaluation and sustainability concerns
  • ↓Operating expenses rose to $990M (+$36M QoQ), pressuring margins
  • ↓Complex payer reimbursement may slow new patient access and uptake
  • ↓Intensifying competition from Janssen and Alexion threatens market share
  • ↓High volatility and rising short interest reflect investor skepticism

Investment themes with ARGX

Demographics Elective Health + Family Care↓ -0.20%

Health services for families and elective treatments

HQY · DOCS · PRVA

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-06-2026neutral

Transcript signals

Bull points

  • Secondly, Carl already explained that I think we're in a strong position from an MFN point of view because we have shown the discipline in the way we have been maintaining, setting and maintaining price in a narrow band globally in our key markets.
  • I think we have strong cards to navigate whatever the future will bring us on these two fronts.
  • We've also seen consistency in where the patients are coming from, and what I mean by that is 85 to 90% of the patients continue to be switched from IVIG or subcutaneous IG to VivGuard.

Bear points

  • After an incredibly strong fourth quarter, we face typical first quarter seasonality in the U.S., which, similar to last year, is primarily due to benefit re-verification.
  • This quarter also marked the first industry-wide impact of Medicare Part D reform, which is accelerating the evolution of our channel mix towards Part D.
  • the majority of the impact you're referring to is to do with the seasonality relating to the re-verification of benefits. that is an industry impact which you always see.
Read full transcript analysis ›